Skip to main content
    A

    AbbVie Inc (ABBV)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $294.64
    -0.39 (-0.13%)

    Market Cap: $521.50B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    AbbVie Inc (ABBV) Financials: Revenue, Profit and Cash Flow

    Updated Oct 30, 2026. Financial statements from company filings, amounts in US dollars.

    AbbVie reported revenue of $61.16B for the fiscal year ended Dec 31, 2025, up 8.6% from the year before. That year, net income was $4.23B with a net margin of 6.9%, operating cash flow was $19.03B and free cash flow was $17.82B. The quarter ended Sep 30, 2026 had revenue of $17.40B and net income of $4.22B.

    Revenue and Margins

    The operating margin was 24.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $25.64B, a compound annual rate of 10.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$61.16B+8.6%62.0%24.6%6.9%
    Dec 2024$56.33B+3.7%70.0%16.2%7.6%
    Dec 2023$54.32B-6.4%62.4%23.5%9.0%
    Dec 2022$58.05B+3.3%68.8%31.2%20.4%
    Dec 2021$56.20B+22.7%69.0%31.9%20.6%
    Dec 2020$45.80B+37.7%63.4%24.8%10.1%
    Dec 2019$33.27B+1.6%77.6%39.0%23.7%
    Dec 2018$32.75B+16.1%76.4%19.5%17.4%
    Dec 2017$28.22B+10.1%75.0%33.8%18.8%
    Dec 2016$25.64BN/A77.3%36.4%23.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income fell 1.4% from the year before. In the quarter ended Sep 2026, net income rose 2144.7% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$61.16B$56.33B$54.32B$58.05B$56.20B$45.80B$33.27B$32.75B$28.22B$25.64B
    Cost of revenue$23.22B$16.90B$20.41B$18.11B$17.45B$16.76B$7.44B$7.72B$7.04B$5.83B
    Gross profit$37.94B$39.43B$33.90B$39.94B$38.75B$29.04B$25.83B$25.04B$21.17B$19.81B
    Research and development$9.10B$12.79B$7.67B$6.51B$6.92B$6.38B$6.79B$10.75B$5.33B$4.58B
    Operating income$15.07B$9.14B$12.76B$18.12B$17.92B$11.36B$12.98B$6.38B$9.54B$9.34B
    Net income$4.23B$4.29B$4.87B$11.85B$11.55B$4.62B$7.88B$5.69B$5.31B$5.95B
    EBITDA$17.36B$14.26B$16.63B$23.99B$23.89B$12.15BN/A$8.11B$10.23B$10.04B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$17.40B$16.99B$15.00B$16.62B$15.78B$15.42B$13.34B$15.10B$14.46B$14.46B$12.31B$14.30B
    Gross profit$12.90B$12.41B$10.04B$9.98B$7.79B$10.25B$9.34B$10.95B$10.17B$10.26B$8.05B$8.81B
    Operating income$6.27B$6.43B$3.99B$4.54B$1.90B$4.89B$3.73B-$1.49B$3.83B$4.00B$2.80B$3.19B
    Net income$4.22B$3.62B$697.00M$1.81B$188.00M$941.00M$1.29B-$23.00M$1.56B$1.37B$1.37B$824.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $67.50B exceeded cash and equivalents by $62.27B. Shareholder equity was negative, at -$3.27B, as total liabilities of $137.19B exceeded total assets of $133.96B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$133.96B$135.16B$134.71B$138.81B$146.53B$150.56B$89.11B$59.35B$70.79B$66.10B
    Current assets$29.06B$25.58B$33.00B$28.46B$27.93B$24.17B$49.52B$16.95B$21.22B$16.19B
    Cash and equivalents$5.23B$5.52B$12.81B$9.20B$9.75B$8.45B$39.92B$7.29B$9.30B$5.10B
    Total liabilities$137.19B$131.80B$124.31B$121.52B$131.09B$137.47B$97.29B$67.80B$65.69B$61.46B
    Short-term debt$8.55B$6.80B$7.19B$4.14B$12.49B$8.50B$3.75B$5.31B$6.42B$402.00M
    Long-term debt$58.94B$60.34B$52.19B$59.13B$64.19B$77.55B$62.98B$49.49B$46.56B$44.79B
    Shareholder equity-$3.27B$3.33B$10.36B$17.25B$15.41B$13.08B-$8.17B-$8.45B$5.10B$4.64B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$147.68B$135.12B$136.46B$133.96B$133.90B$137.18B$136.16B$135.16B$143.42B$141.94B$148.87B$134.71B
    Total liabilities$152.22B$141.00B$143.07B$137.19B$136.50B$137.32B$134.70B$131.80B$137.35B$135.12B$140.83B$124.31B
    Cash and equivalents$10.77B$6.57B$9.39B$5.23B$5.63B$6.47B$5.17B$5.52B$7.26B$13.13B$18.07B$12.81B
    Shareholder equity-$4.58B-$5.93B-$6.66B-$3.23B-$2.64B-$183.00M$1.42B$3.36B$6.03B$6.78B$8.01B$10.40B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 93.6% of operating cash flow. Dividends and share repurchases together came to 71.0% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$19.03B$18.81B$22.84B$24.94B$22.78B$17.59B$13.32B$13.43B$9.96B$7.04B
    Capital expenditures$1.21B$974.00M$777.00M$695.00M$787.00M$798.00M$552.00M$638.00M$529.00M$479.00M
    Free cash flow$17.82B$17.83B$22.06B$24.25B$21.99B$16.79B$12.77B$12.79B$9.43B$6.56B
    Dividends paid$11.66B$11.03B$10.54B$10.04B$9.26B$7.72B$6.37B$5.58B$4.11B$3.72B
    Share repurchases$1.00B$1.81B$2.01B$1.49B$934.00M$998.00M$1.05B$12.05B$1.41B$6.10B
    Investing cash flow-$6.64B-$20.82B-$2.01B-$623.00M-$2.34B-$37.56B$596.00M-$1.01B-$274.00M-$6.07B
    Financing cash flow-$12.72B-$5.21B-$17.22B-$24.80B-$19.04B-$11.50B$18.71B-$14.40B-$5.51B-$3.93B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$7.61B$3.44B$3.83B$5.22B$7.02B$5.15B$1.64B$7.05B$5.45B$2.27B$4.04B$4.75B
    Capital expenditures$301.00M$322.00M$265.00M$329.00M$381.00M$269.00M$235.00M$291.00M$249.00M$241.00M$193.00M$205.00M
    Free cash flow$7.30B$3.11B$3.56B$4.89B$6.64B$4.88B$1.40B$6.76B$5.20B$2.03B$3.85B$4.55B
    Last 12 quarters

    Frequently Asked Questions About ABBV

    What is AbbVie's annual revenue?

    AbbVie reported revenue of $61.16B for the fiscal year ended Dec 31, 2025.

    How fast is AbbVie's revenue growing?

    Revenue was up 8.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 1.8%.

    Is AbbVie profitable?

    Yes. AbbVie reported net income of $4.23B for the fiscal year ended Dec 31, 2025, with a net margin of 6.9%.

    How much free cash flow does ABBV generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $19.03B minus capital expenditures of $1.21B produced free cash flow of $17.82B.

    How much debt does AbbVie have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $58.94B, short-term debt of $8.55B and cash and equivalents of $5.23B.